This page shows the latest Trajenta news and features for those working in and with pharma, biotech and healthcare.
Boehringer already has an existing relationship with Yuhan, which acts as the South Korean marketer for three of the German firm’s Eli Lilly-partnered diabetes therapies, Tradjenta (linagliptin), Trajenta Duo
In particular, Eli Lilly-partnered diabetes franchise based on DPP-4 inhibitor Trajenta (linagliptin) climbed 23% to 1.1bn while sales of lung disease therapy Ofev (nintedanib) more than doubled to
Sudler &Hennessey London's diabetes iPad game, 'The Journey Ahead Challenge' for Trajenta EASD Congress Activity also made the cut. ... The campaign saw players earn 'fuel' in the driving game by answering questions about diabetes and Trajenta's brand.
Sales of DPP-4 inhibitor Trajenta (linagliptin) and its Jentadueto (linagliptin and metformin) combination rose 42.9% to 909m. ... The company will not publish separate sales figures for Trajenta and Jentadueto until next year, but said 2015's
Healthcare Professional - Digital Media. 'The Road Ahead Challenge' for Trajenta, by Sudler London .
1% increase to reach 5.4bn thanks to higher sales of its Trajenta (linagliptin) franchise. ... Trajenta and combination product Jentadueto (linagliptin and metformin) climbed 22% to 419m in the six-month period, although this growth rate is well below
More from news
Approximately 1 fully matching, plus 25 partially matching documents found.
Secondly, growth is ebbing away from Forxiga (dapagliflozin), the first entrant of the DPP4s, which is actually growing slightly slower than Trajenta. ... The key points here are that Trajenta is used by just under 8, 000 practices but appears to have
This includes Germany-based Boehringer Ingelheim's disapproval of the generic comparator used in IQWiG's AMNOG assessment of the diabetes medicine Trajenta (linagliptin).
The launch of Trajenta has been positive in many markets around the world. ... reimbursement body IQWIG refusing to recommend several new drugs, including Boehringer's diabetes treatment Trajenta.
Ingelheim and Eli Lilly's Type 2 diabetes drug Trajenta (linagliptin).
6. Less than comparator. It is significant that last year, BI and Lilly decided not to launch their new diabetes drug Trajenta in Germany, blaming price controls. ... Out of the 10 products assessed last year, four have obtained poor innovation scores:
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...